Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
Authors:
- 1 January 2020
- journal article
- review article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 18 (1) , 69-81.e3
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institutes of Health (K23DK117058)
- National Institutes of Health
This publication has 41 references indexed in Scilit:
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative ColitisGastroenterology, 2014
- Assessing Bias in Studies of Prognostic FactorsAnnals of Internal Medicine, 2013
- Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ RegistryAmerican Journal of Gastroenterology, 2012
- Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune DiseasesJAMA, 2011
- Serious infections in patients with inflammatory bowel disease receiving anti‐tumor‐necrosis‐factor‐alpha therapy: An Australian and New Zealand experienceJournal of Gastroenterology and Hepatology, 2010
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infectionsAlimentary Pharmacology & Therapeutics, 2009
- Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort studyGut, 2008
- Measuring inconsistency in meta-analysesBMJ, 2003
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986